Please use this identifier to cite or link to this item:
|Authors:||Alvarenga, Lênio Souza [UNIFESP]|
Mannis, Mark J. [UNIFESP]
Univ Calif Davis
Universidade Federal de São Paulo (UNIFESP)
|Publisher:||Ethis Communicatins, Inc|
|Citation:||Ocular Surface. New York: Ethis Communicatins, Inc, v. 3, n. 1, p. 41-58, 2005.|
|Abstract:||Rosacea is a common skin disease that frequently involves the eye. Although the pathogenesis of the disease remains undefined, recent findings suggest that an altered inflammatory response plays an important role in both cutaneous and ocular rosacea. Ocular manifestations include lid and ocular surface alterations. Chronic inflammation can lead to corneal vascularization, which may compromise vision. Treatment of ocular rosacea is aimed at preventing irritation of the ocular surface (e.g., lubricants, lid hygiene) and controlling inflammation with topical and systemic anti-inflammatory drugs. Systemic tetracyclines are the mainstay of treatment. These drugs act multifactorially by decreasing bacterial flora and the expression of matrix metalloproteinases, altering meibum secretion, inhibiting the production of bacterial lipases, and providing an immunomodulatory effect.|
|Appears in Collections:||Resenha|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.